pembrolizumab
merck
['bcsm']
dr. stringer-reasor eloquently discusses our #bcsm neoadjuvant presentations: rcb associates with efs and drfs across all subtypes in kn522, those with rcb 0 or 1 did very well. #immunotherapy not without toxicity (iraes 33% w/ immuno vs. 11% chemo alone) #asco22 
Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine.